Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: results from the prospective Predi-COVID cohort study

Laurent Malisoux, Anne Backes, Aurélie Fischer, Gloria Aguayo, Markus Ollert, Guy Fagherazzi

ABSTRACT

Objective To investigate if the physical activity (PA) prior to infection is associated with the severity of the disease in patients positively tested for COVID-19, as well as with the most common symptoms.

Design A cross-sectional study using baseline data from a prospective, hybrid cohort study (Predi-COVID) in Luxembourg. Data were collected from May 2020 to June 2021.

Setting Real-life setting (at home) and hospitalised patients.

Participants All volunteers aged >18 years with confirmed SARS-CoV-2 infection, as determined by reverse transcription-PCR, and having completed the PA questionnaire (n=452).

Primary and secondary outcome measures The primary outcome was disease severity (asymptomatic, mild illness and moderate illness). The secondary outcomes were self-reported symptoms.

Results From the 452 patients included, 216 (48%) were female, the median (IQR) age was 42 (31–51) years, 59 (13%) were classified as asymptomatic, 287 (63%) as mild illness and 106 (24%) as moderate illness. The most prevalent symptoms were fatigue (n=294; 65%), headache (n=281; 62%) and dry cough (n=241; 53%). After adjustment, the highest PA level was associated with a lower risk of moderate illness (OR 0.37; 95% CI 0.32 to 0.96, p=0.010) and chest pain (OR 0.32; 95% CI 0.30 to 0.97, p=0.040), dry cough (OR 0.55; 95% CI 0.32 to 0.96, p=0.034) and chest pain (OR 0.32; 95% CI 0.14 to 0.77, p=0.010).

Conclusions PA before COVID-19 infection was associated with a reduced risk of moderate illness severity and a reduced risk of experiencing fatigue, dry cough and chest pain, suggesting that engaging in PA may be an effective approach to minimise the severity of COVID-19.

INTRODUCTION

COVID-19, caused by SARS-CoV-2, spreads rapidly from China, caused outbreaks in countries throughout the world and was characterised by the WHO as a global pandemic on 11 March 2020. This pandemic overwhelmed healthcare facilities, including but not limited to hospitals, intensive care units (ICUs) and outpatient facilities. Epidemiological studies have demonstrated that mortality is higher among the elderly population, with a 6.1% increase in mortality per 10 years increase in age. The risk for serious disease and death related to COVID-19 have been shown to be associated with baseline characteristics of patients such as old age, obesity, heavy smoking, as well as underlying conditions or comorbidities such as autoimmunity, genetic errors of immunity, hypertension, respiratory disease and cardiovascular disease.

Physical activity (PA) is one of the leading determinants of health, and thus, lack of PA may worsen the impact of the current pandemic. Indeed, the risk of developing severe disease appears to be lower among those who are physically active compared to those who are sedentary. No definitive studies have evaluated the role of PA in the severity and course of COVID-19.
chronic diseases is much higher in those with low PA,\textsuperscript{8,9} while COVID-19 patients with such underlying medical conditions (eg, obesity and diabetes) are more likely to be hospitalised and have a greater likelihood in poorer clinical outcomes.\textsuperscript{10} It is also well established that insufficient levels of PA lead to reduced respiratory and cardiovascular capacities, which can lead to a greater occurrence of obesity and other chronic diseases.\textsuperscript{11} Moreover, there is growing evidence that PA has a protective effect against infectivity and severity of respiratory infection due probably to a better immunological response.\textsuperscript{12} Consequently, one may argue that both low PA, an important modifiable factor and high chronic disease prevalence worsen the severity of the crisis we are currently facing.

To date, the heterogeneity in the response to the infection to SARS-CoV-2 remains largely unexplained. COVID-19 symptoms are very heterogeneous and can range from minimal to significant severity in an infected individual.\textsuperscript{13} A systematic review including 152 studies and 41,409 individuals showed that the most common symptoms were fever (59%), cough (55%), dyspnoea (31%), malaise (30%), fatigue (28%), sore throat (14%), headache (12%) and chest pain (11%).\textsuperscript{14} While it has been demonstrated that PA decreases the risk of severe clinical COVID-19 outcomes (eg, hospitalisation or death),\textsuperscript{15,16} there is still limited information on the impact of PA on the severity of COVID-19 in patients with less severe disease and on the risk of developing specific symptoms. Therefore, the primary objective of this study was to investigate if the level of PA over the year prior to infection is associated with the severity of the disease in patients positively tested for COVID-19. The secondary objective was to investigate if PA is associated with the most common symptoms: headache, sore throat, fever, dry cough, diarrhoea, breathing difficulties, loss of taste and smell, chest pain, muscle pain, fatigue, confusion and falls. We hypothesised that higher level of PA prior to infection would be associated with less severe forms of COVID-19, as well as with less frequent reports of the major COVID-19-related symptoms.

METHODS

Study design and participants

This is a cross-sectional study using data from a prospective, hybrid cohort study (Predi-COV\textsuperscript{20}D) composed of people positively tested for COVID-19 in Luxembourg.\textsuperscript{2} The Predi-COV\textsuperscript{20}D study aims to identify epidemiological, clinical and sociodemographic characteristics as well as pathogen and/or host predictive biomarkers for the severity of COVID-19. The full study protocol has been published previously,\textsuperscript{2} with some of the methods that are relevant to this study reproduced below. All volunteers received a full description of the protocol and provided written informed consent for participation. The findings from this study have been reported according to the Strengthening the Reporting of Observational Studies in Epidemiology statement.\textsuperscript{17}

All individuals positively tested for COVID-19 in Luxembourg were eligible for the study and contacted by phone by the Health Inspection to enquire whether they consent to having their contact details communicated to the research team. The recruitment took place between May 2020 and June 2021. Inclusion criteria for this study were: having signed the informed consent, aged above 18 years, confirmed SARS-CoV-2 infection as determined by reverse transcription PCR (RT-PCR), performed by one of the certified laboratories in Luxembourg, and having completed the questionnaire on PA behaviour. Patients already included in another interventional study on COVID-19 and those unable to understand French or German were excluded from the study. The recruitment of participants depended on the emergence and spread of the virus and the resources available.

Patient and public involvement

No patient or public involved.

Outcomes

All clinical data were collected at baseline by research nurses using a modified version of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) case report form. The primary outcome was the severity of illness, which was classified using an adapted version of the National Institute of Health symptom severity classification scheme.\textsuperscript{18} Participants were grouped into the following three categories: asymptomatic (positive RT-PCR test and no symptom), mild illness (positive RT-PCR test and one or more symptoms, but no shortness of breath, no symptoms of lower respiratory disease, no abnormal chest imaging) and moderate illness (positive RT-PCR test and symptoms of lower respiratory disease or abnormal chest imaging). The secondary outcomes were specific symptoms reported by the participants at baseline. The presence of the following twelve symptoms was considered for the present work: headache, sore throat, fever, dry cough, diarrhoea, breathing difficulties, loss of taste and smell, chest pain, muscle pain, fatigue, confusion and falls.

Exposures

The exposure was PA over the year prior to infection, which was assessed using a self-reported e-questionnaire using the electronic patient-reported outcomes module of Ennov Clinical. The PA questionnaire included questions on weekly hours spent walking (to work, shopping and leisure time), cycling (to work, shopping and leisure time), gardening (and other handiwork), in household chores and sports activities (eg, racket sports, swimming, running) in the year prior to infection, each reported for winter and summer, separately.\textsuperscript{19} The time reported for the two seasons was first averaged. Then each activity was assigned a metabolic equivalent task (MET) value based on the Compendium of PA,\textsuperscript{20} which included MET values of 3.0 for walking and household, 4.0 for gardening and 6.0 for cycling and sports. A total weekly METs score
Cubic spline regression models were plotted to investigate the potential non-linear associations between PA and the risk of mild and moderate illness severity, compared with an asymptomatic form, as well as between PA and the risk of specific symptoms. Each cubic spline regression model was defined with four knots, placed at the tertiles of the PA distribution, and with a reference exposure value set at the median of PA for disease severity or a specific symptom, respectively. The splines R package was used to fit the models.

All the statistical analyses were performed in R (V.3.6.1) using RStudio (V.1.3.1093). Statistical significance was set to p<0.05.

RESULTS

The analysis includes 452 adults, aged (IQR) 42 (31–51) years old, with confirmed SARS-CoV-2 infection who agreed to participate in the study and provided data on PA. Only five participants were hospitalised, but none of them was admitted to ICU. Thirteen per cent of the participants were asymptomatic (n=59), 63% were classified as mild illness (n=287), and 24% as moderate illness (n=106). The most prevalent symptoms were fatigue (n=294; 65%), headache (n=281; 62%), dry cough (n=241; 53%), muscle pain (n=237; 52%), sore throat (n=203; 45%), fever (n=197; 44%) and loss of taste and smell (n=179; 40%). Breathing difficulties (n=101; 22%), diarrhoea (n=89; 20%), chest pain (n=69; 15%), confusion (n=51; 10%) and falls (n=2; <1%) were less common.

Descriptive statistics of the study population stratified by illness severity are presented in table 1. Overall, the study population included 48% of women (n=216), median age was 42 (IQR: 31–51), BMI was 24.9 (IQR: 22.1–27.8) and 79% did not suffer from any comorbidity (n=359). Missing data varied from 0% to 5%. The variables that had missing data were income (n=21; 5%), sedentary behaviour (n=51; 10%) and falls (n=2; <1%) were less common.

Table 2 presents the unadjusted and adjusted models for the association between PA and disease severity. When PA was considered as a continuous variable, no association was found with mild or moderate forms of COVID-19 in the unadjusted model. After adjustment, greater PA was associated with a slightly lower risk of moderate illness (OR (95% CI): 0.37 (0.14 to 0.98), p=0.041). Cubic spline regression analysis showed that the relationship between PA and the risk of mild or moderate illness was not linear (figure 1), which supports the use of PA as a categorical variable. The unadjusted model did not reveal any association between PA categories and mild or moderate illness. However, the adjusted model showed a lower risk of moderate illness in the category with the highest PA level (OR (95% CI): 0.37 (0.14 to 0.98), p=0.045).

The associations between PA and specific symptoms in the adjusted models are presented in table 3. Greater PA was associated with a lower risk of chest pain (OR (95% CI): 0.99 (0.98 to 1.00), p=0.007) when PA was considered...
as a continuous variable. The category with the highest PA level was associated with lower risk of fatigue (OR (95% CI): 0.54 (0.30 to 0.97), p=0.040), dry cough (OR (95% CI): 0.55 (0.32 to 0.96), p=0.034) and chest pain (OR (95% CI): 0.32 (0.14 to 0.77), p=0.010). Figure 2 shows separate cubic splines investigating the association between PA and specific COVID-19 symptoms.

**DISCUSSION**

The protective effect of meeting PA recommendations on the risk of severe COVID-19 outcomes (ie, death, ICU admission and hospitalisation) has previously been documented. However, whether PA may also prevent less severe illness courses remains unknown. The primary objective of this study was to investigate if the level of PA over the year prior to infection is associated with the severity of the disease in patients positively tested for COVID-19. The secondary objective was to investigate if PA is associated with the most common symptoms such as fatigue, headache, dry cough, muscle pain, sore throat, fever and loss of taste and smell. We hypothesised that higher level of PA prior to the infection would be associated with lower risk of mild and moderate illness, and lower risk of suffering from some of the most commonly reported symptoms. Our main findings were that participants with greater PA were at a lower risk of moderate COVID-19 severity, which confirms our hypothesis. Furthermore, greater level of PA was also associated with a decreased risk of experiencing fatigue, dry cough and chest pain, which are among the most commonly reported symptoms in patients positively tested for COVID-19. These findings suggest that PA is a protective factor for

| Characteristic                  | All (n=452) MED (IQR) or n (%) | Disease severity | All (n=452) MED (IQR) or n (%) | Disease severity | All (n=452) MED (IQR) or n (%) | Disease severity | All (n=452) MED (IQR) or n (%) | Disease severity |
|--------------------------------|--------------------------------|-----------------|--------------------------------|-----------------|--------------------------------|-----------------|--------------------------------|-----------------|
| Age (years)*                   | 42 (31–51)                     | Asymptomatic (n=59) MED (IQR) or n (%) | 43 (31–56) | Mild illness (n=287) MED (IQR) or n (%) | 41 (31–51) | Moderate illness (n=106) MED (IQR) or n (%) | 42 (32–49) |
| Sex                            |                                |                 |                                |                 |                                |                 |                                |                 |
| Female                         | 216 (47.8)                     | 19 (32.2)       | 134 (46.7)                     | 63 (59.4)       |                                |                 |                                |                 |
| Male                           | 236 (52.2)                     | 40 (67.8)       | 153 (53.3)                     | 43 (40.6)       |                                |                 |                                |                 |
| BMI (kg/m²)*                   | 24.9 (22.1, 27.8)              | 25.5 (22.2, 28.2) | 24.7 (22.1, 27.5)              | 25.5 (22.2, 29.2) |                                |                 |                                |                 |
| Comorbidities                  |                                |                 |                                |                 |                                |                 |                                |                 |
| No comorbidities               | 359 (79.4)                     | 42 (71.2)       | 243 (84.7)                     | 74 (69.8)       |                                |                 |                                |                 |
| At least one comorbidity       | 93 (20.6)                      | 17 (28.8)       | 44 (15.3)                      | 32 (30.2)       |                                |                 |                                |                 |
| Smoking status*                |                                |                 |                                |                 |                                |                 |                                |                 |
| Never smoker                   | 291 (64.4)                     | 34 (57.6)       | 184 (64.1)                     | 73 (68.9)       |                                |                 |                                |                 |
| Former smoker                  | 84 (18.6)                      | 13 (22.0)       | 55 (19.2)                      | 16 (15.1)       |                                |                 |                                |                 |
| Current smoker                 | 77 (17.0)                      | 12 (20.3)       | 48 (16.7)                      | 17 (16.0)       |                                |                 |                                |                 |
| Income (euro/month)*           |                                |                 |                                |                 |                                |                 |                                |                 |
| <€3000                         | 71 (15.7)                      | 11 (18.6)       | 39 (13.6)                      | 21 (19.8)       |                                |                 |                                |                 |
| €3000–€4999                    | 110 (24.3)                     | 15 (25.4)       | 70 (24.4)                      | 25 (23.6)       |                                |                 |                                |                 |
| €5000–€10 000                  | 203 (44.9)                     | 23 (39.0)       | 138 (48.1)                     | 42 (39.6)       |                                |                 |                                |                 |
| >€100000                      | 68 (15.0)                      | 11 (18.6)       | 40 (13.9)                      | 18 (17.0)       |                                |                 |                                |                 |
| Sedentary behaviour (hour/day)*| 7 (4, 10)                      | 6 (4, 10)       | 7 (4, 10)                      | 6 (4, 9)        |                                |                 |                                |                 |
| Physical activity (MET-hour/week) | 52.9 (30.8, 82.3) | 63.0 (40.3, 98.5) | 52.0 (31.4, 81.0) | 49.3 (27.4, 73.9) |                                |                 |                                |                 |
| Physical activity (MET-hour/week) | <30                         | 108 (23.9)      | 10 (16.9)                      | 68 (23.7)       | 30 (28.3)                      |                 |                                |                 |
|                                 | 30–52                          | 113 (25.0)      | 13 (22.0)                      | 75 (26.1)       | 25 (23.6)                      |                 |                                |                 |
|                                 | 52–82                          | 116 (25.7)      | 16 (27.1)                      | 74 (25.8)       | 26 (24.5)                      |                 |                                |                 |
|                                 | >82                            | 115 (25.4)      | 20 (33.9)                      | 70 (24.4)       | 25 (23.6)                      |                 |                                |                 |

*Imputed data were used for the descriptive statistics.
BMI, body mass index; MED, median; MET, metabolic equivalent task.
the development of moderate COVID-19 course in adults and for some common related symptoms.

Previous studies have shown that insufficient PA prior to the pandemic increased the risk of hospitalisation, admission to ICU and death. Notably, low PA was shown to be one of the stronger risk factors for severe COVID-19 outcome, after advanced age and history of organ transplant. Furthermore, meeting the PA guidelines has been shown to decrease the risk of SARS-CoV-2 infection in adult Koreans, beside the negative association with the risk of severe COVID-19 illness (ICU admission or administration of invasive ventilation) and COVID-19-related death. Objective measures of PA have also demonstrated a decreased risk of contracting COVID-19 and hospitalisation in those with greater PA. A study including only patients with chest CT scan confirming infection showed that physical inactivity was associated with the severity of COVID-19 disease. Overall, these previous studies suggested a protective effect of PA for severe COVID-19 outcomes, while some of these studies only included severe cases. While our findings are in line with these previous observations as they confirm the benefits of PA for COVID-19 severity, this is the first study to demonstrate that PA can also provide a protective effect for moderate courses.

Previous scientific literature has supported the role of PA against upper respiratory tract infections. Research on the 2009 H1N1 influenza epidemic demonstrated a dose–response relationship between PA performed before infection and a reduction in the incidence, duration, or severity of acute upper respiratory tract infections. During seasonal influenza, moderately active and active individuals were approximately 15% less likely to visit a physician or emergency services due to influenza compared with inactive individuals. A recent meta-analysis revealed that people engaged in higher levels of PA showed a 31% risk reduction for community-acquired infectious disease.

PA can play a protective role against respiratory viral infections and have important roles in a pandemic through three main mechanisms. First, PA has an indirect protective effect by improving cardiovascular and respiratory functions (ie, the endurance and strength of the respiratory muscles) and lowering the risk of chronic diseases. Consistently, maximal exercise capacity prior SARS-CoV-2 infection was shown to be inversely associated with the risk of hospitalisation due to COVID-19. Exercise capacity is greatly influenced by PA, and more specifically regular moderate-intensity to severe activity was associated with the severity of COVID-19 disease.

### Table 2: Associations between physical activity and illness severity

| Exposure | Outcome | Model 1 | Model 2 |
|----------|---------|---------|---------|
| Model 1  | OR (95% CI) | P value | OR (95% CI) | P value |
| Model 2  | adjusted for age, sex, BMI, comorbidities, smoking status, income and sedentary behaviour. |
| PA (MET-hour/week) | Disease severity† | | |
| Mild illness | 0.99 (0.99 to 1.00) | 0.106 | 0.99 (0.99 to 1.00) | 0.064 |
| Moderate illness | 0.99 (0.99 to 1.00) | 0.068 | 0.99 (0.98 to 1.00) | 0.041* |
| PA (MET-hour/week)‡ | Disease severity† | | |
| 30–52 Mild illness | 0.85 (0.35 to 2.06) | 0.717 | 0.75 (0.30 to 1.88) | 0.542 |
| 52–82 Mild illness | 0.68 (0.29 to 1.60) | 0.378 | 0.55 (0.22 to 1.34) | 0.185 |
| >82 Mild illness | 0.51 (0.22 to 1.18) | 0.117 | 0.46 (0.19 to 1.08) | 0.075 |
| 30–52 Moderate illness | 0.64 (0.24 to 1.71) | 0.374 | 0.57 (0.20 to 1.58) | 0.278 |
| 52–82 Moderate illness | 0.54 (0.21 to 1.40) | 0.205 | 0.48 (0.18 to 1.29) | 0.145 |
| >82 Moderate illness | 0.42 (0.16 to 1.05) | 0.064 | 0.37 (0.14 to 0.98) | 0.045* |
| P-trend Mild illness | 0.99 (0.98 to 1.01) | 0.374 | 0.99 (0.97 to 1.01) | 0.243 |
| P-trend Moderate illness | 0.99 (0.97 to 1.01) | 0.203 | 0.99 (0.97 to 1.01) | 0.171 |

Values are presented as OR (95% CI), which were calculated according to Rubin’s rule. All models were performed with imputed data. Model 1 = unadjusted model; Model 2 = model 1 adjusted for age, sex, BMI, comorbidities, smoking status, income and sedentary behaviour. *P<0.05.

†Reference: asymptomatic
‡Reference: <30 MET-hour/week
BMI, body mass index; MET, metabolic equivalent task; PA, physical activity.

### Figure 1: Cubic spline regression investigating the association between physical activity and disease severity.

Reference exposure value set at the median of physical activity (52.9 MET-hour/week). MET, metabolic equivalent task.
Table 3  Associations between physical activity and specific COVID-19 symptoms using the adjusted model 2

| Exposure | Outcome | OR (95% CI) | P value |
|----------|---------|-------------|---------|
| PA (MET-hour/week) | Symptom |             |         |
|          | Fatigue | 1.00 (0.99 to 1.00) | 0.130   |
|          | Headache | 1.00 (0.99 to 1.00) | 0.181   |
|          | Muscle pain | 1.00 (0.99 to 1.00) | 0.442   |
|          | Dry cough | 1.00 (0.99 to 1.00) | 0.056   |
|          | Sore throat | 1.00 (1.00 to 1.00) | 0.973   |
|          | Fever | 1.00 (0.99 to 1.00) | 0.453   |
|          | Loss of taste and smell | 1.00 (0.99 to 1.00) | 0.286   |
|          | Breathing difficulties | 1.00 (0.99 to 1.00) | 0.348   |
|          | Diarrhoea | 1.00 (0.99 to 1.00) | 0.577   |
|          | Chest pain | 0.99 (0.98 to 1.00) | 0.007*  |
|          | Confusion | 1.00 (0.99 to 1.01) | 0.804   |

| PA (MET-hour/week)† | Symptom |          |         |
|---------------------|---------|---------|---------|
| 30–52               | Fatigue | 0.63 (0.35 to 1.15) | 0.130   |
| 52–82               | 0.69 (0.37 to 1.25) | 0.218   |
| >82                 | 0.54 (0.30 to 0.97) | 0.040*  |
| 30–52               | Headache | 1.10 (0.62 to 1.94) | 0.745   |
| 52–82               | 1.07 (0.61 to 1.89) | 0.807   |
| >82                 | 0.73 (0.42 to 1.26) | 0.256   |
| 30–52               | Muscle pain | 0.80 (0.46 to 1.39) | 0.430   |
| 52–82               | 1.15 (0.67 to 1.99) | 0.615   |
| >82                 | 0.68 (0.40 to 1.18) | 0.171   |
| 30–52               | Dry cough | 0.66 (0.38 to 1.16) | 0.145   |
| 52–82               | 0.69 (0.40 to 1.21) | 0.196   |
| >82                 | 0.55 (0.32 to 0.96) | 0.034*  |
| 30–52               | Sore throat | 1.24 (0.71 to 2.16) | 0.453   |
| 52–82               | 1.34 (0.77 to 2.33) | 0.297   |
| >82                 | 1.19 (0.69 to 2.07) | 0.531   |
| 30–52               | Fever | 0.97 (0.56 to 1.69) | 0.924   |
| 52–82               | 0.90 (0.52 to 1.56) | 0.700   |
| >82                 | 0.89 (0.51 to 1.54) | 0.675   |
| 30–52               | Loss of taste and smell | 1.02 (0.58 to 1.79) | 0.947   |
| 52–82               | 1.09 (0.62 to 1.90) | 0.769   |
| >82                 | 0.84 (0.47 to 1.48) | 0.539   |
| 30–52               | Breathing difficulties | 0.64 (0.33 to 1.25) | 0.190   |
| 52–82               | 0.86 (0.45 to 1.62) | 0.634   |
| >82                 | 0.72 (0.38 to 1.37) | 0.318   |
| 30–52               | Diarrhoea | 0.72 (0.36 to 1.43) | 0.343   |
| 52–82               | 0.94 (0.49 to 1.82) | 0.862   |
| >82                 | 0.70 (0.36 to 1.39) | 0.313   |
| 30–52               | Chest pain | 0.80 (0.39 to 1.65) | 0.553   |
| 52–82               | 0.87 (0.43 to 1.78) | 0.705   |
| >82                 | 0.32 (0.14 to 0.77) | 0.010*  |
| 30–52               | Confusion | 1.04 (0.40 to 2.69) | 0.941   |
| 52–82               | 2.16 (0.91 to 5.09) | 0.079   |
| >82                 | 0.99 (0.38 to 2.61) | 0.982   |

Values are presented as OR (95% CI), which were calculated according to Rubin’s rule. All models were performed with imputed data.

*P<0.05.
†Reference: <30 MET-hour/week.
MET, metabolic equivalent task; PA, physical activity.
vigor-intensity aerobic exercise. The authors argued that exercise capacity is an important measure of overall health, the ability of the body to respond to external stressors, and more specifically, the ability to tolerate cardiopulmonary burden.35

Second, the immune system is very responsive to PA and exercise, with the extent and duration depending on the degree of physiological stress imposed by the workload. Importantly, most of the literature on the effect of PA on human immunity investigated acute effects of exercises and focused on athletes, which call for caution when generalising the findings. Globally, the beneficial effect of regular PA on the immune system may involve several mechanisms such as enhanced immunosurveillance, reduced systemic inflammation and improved regulation of the immune system as well as delayed onset of immunosenescence.34,35 A recent systematic review investigated the effects of regular PA on the immune system.12 Interventions including 3–5 sessions per week for an average of 30 min at moderate to vigorous intensity (eg, walking, running, cycling) resulted overall in a lower concentration of neutrophils, as well as a higher concentrations of CD4 T helper cells and salivary IgA. The lower concentration of neutrophil may be interpreted as a consequence of the beneficial effect of regular PA on chronic inflammation.36 CD4 T cells contribute to a rapid and more robust immune response. Salivary IgA can be regarded as the first line of defence of the immune system on the mucosal surface and plays other roles such as downregulating inflammation processes.37 Among others, experimental studies have also showed that moderate intensity PA stimulates an increase in the antipathogen activity of immune system macrophages and anti-inflammatory cytokines in the blood, together resulting in a reduced influx of inflammatory cells into the lungs.29

Third, PA may also enhance vaccination response38 39 and has a direct impact on trained immunity of innate immune cells such as Kupffer cells in the liver.40 Trained immunity on the other hand, which describes a long-term boost through metabolic and epigenetic reprogramming of the innate immune response by certain stimuli (such as BCG vaccination or PA), has been proposed as an important tool for reducing susceptibility to and severity of COVID-19.41

Some studies have described a J shaped association between exercise volume and infection with optimal protection at moderate levels of activity.42 In this study, the cubic spline plots showed that the relationships between PA and COVID-19 severity and symptoms occurrence were not linear, but our sample size did not enable to define the shape of the curve accurately.

One of the limitations of this study was the use of self-reported measures to assess PA, which might have resulted in recall bias, compared with exposure assessment measured using objective means (ie, accelerometers), which can provide a more accurate assessment of the true level of PA. However, our PA assessment tool has previously been used in large cohort studies,19 43 and covers all the PA domains (ie, occupational, transport, leisure-time, household/gardening). Nevertheless, the use of self-report questionnaires usually leads to overestimation of PA, which may lead to underestimation of the magnitude of true associations.44 Second, there was no measure of PA intensity, although each activity was assigned a specific MET value. Third, this study was an observational study with a limited sample size for some outcome categories. It is not possible to conclude that PA prior to infection is causally related to less severe COVID-19 outcomes as this study design suffers from a potential issue of residual confounding due to unmeasured or unknown confounders. However, our adjusted model controlled for all the most relevant confounders identified so far. Fourth, some estimated 95% CI suggest sparse data bias (see tables 2 and 3), which should be recognised as an important limitation.

CONCLUSION
We found that greater PA prior to infection was associated with a reduced risk of moderate illness severity among adults positively tested for COVID-19. Greater PA was also associated with a reduced risk of experiencing
fatigue, dry cough and chest pain, which are among the most commonly reported symptoms in patients with COVID-19. This study provides new evidence that PA is a modifiable risk factor for COVID-19 severity, including moderate illness. Our findings suggest that engaging in regular PA may be one of the key actions individuals can take to minimise adverse consequences of COVID-19.

**Twitter** Laurent Malisoux @LaurentMalisoux

**Acknowledgements** We are thankful to the study participants, the Predi-COVID study group and the funders for their support of this initiative. The Predi-COVID study is supported by the Luxembourg National Research Fund (FNR) (Predi-COVID, grant number 14716273), the André Losch Foundation and by European Regional Development Fund (FEDER, convention 2018-04-026-21).

**Contributors** LM, AB, AF, GA, MO and GF contributed sufficiently to the manuscript to justify authorship. LM, AF, GA, MO and GF conceptualised the project, and LM, AB, GA and GF defined the methodology for the present study. LM and AB verified the underlying data and conducted the data analysis. All authors were involved in the interpretation of the analysis results. LM drafted the first manuscript and all other authors provided significant feedback and comments to refine the final manuscript. All authors approved the final manuscript and confirm that they accept responsibility to submit for publication. LM acts as a guarantor for the manuscript.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** The study was approved by the National Research Ethics Committee of Luxembourg (CNER) in April 2020 (ID: 202003/07).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. As this is a cross-sectional analysis of baseline data from a currently ongoing prospective study, the data will not be made available publicly before the end of the Predi-Covid study. The study protocol can be found under https://bmjopen.bmj.com/content/10/11/e041834.abstract.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, and transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iD**

Laurent Malisoux http://orcid.org/0000-0002-6601-5630

**REFERENCES**

1 Liu Y-C, Kuo R-L, Shih S-R. COVID-19: the first documented coronavirus pandemic in history. *Biomed J* 2020;43:328–33.

2 Fagherazzi G, Fischer A, Betsou F, et al. Protocol for a prospective, longitudinal cohort of people with COVID-19 and their household members to study factors associated with disease severity: the Predi-COVID study. *BMJ Open* 2020;10:e041834.

3 Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. *PLOS One* 2020;15:e0241955.

4 Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in ~1% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. *Sci Immunol* 2021;6:eabi4340.

5 Asano T, Boisson B, Onodii F, et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. *Sci Immunol* 2021;6:eabi4348.

6 Jordan RE, Adap A, Cheng K. Covid-19: risk factors for severe disease and death. British Medical Journal Publishing Group, 2020.

7 Lee I-M, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet* 2012;380:219–29.

8 Lacombe J, Armstrong MEG, Wright FL, et al. The impact of physical activity and an additional behavioural risk factor on cardiovascular disease, cancer and all-cause mortality: a systematic review. *BMJ Public Health* 2019;19:900.

9 Wahi A, Maneek N, Nicholls M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. *J Am Heart Assoc* 2016;5:e002495.

10 Bialek S, Bounds E, Bowen V, et al. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12–March 16, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:343–6.

11 Sten G, Dapone E, Seland H, et al. Sedentary behavior and cardiovascular health. *Circ Res* 2019;124:799–815.

12 Chastin SFM, Abaaroa U, Bourgois JG, et al. Effects of regular physical activity on the immune system, vaccination and risk of community-acquired infectious disease in the general population: systematic review and meta-analysis. *Sports Med* 2021;51:1673–86.

13 Yuki K, Fujii M, Koutsogiannaki S. COVID-19 pathophysiology: a review. *Clim Immunol* 2020;215:108427.

14 da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, et al. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien Klin Wochenschr* 2021;133:377–82.

15 Lee SW, Lee J, Moon SY, et al. Physical activity and the risk of SARS-CoV-2 infection, severe COVID-19 illness and COVID-19 related mortality in South Korea: a nationwide cohort study. *Br J Sports Med* 2021;doi:10.1136/bjsports-2021-104203. [Epub ahead of print]: 22 Jul 2021.

16 Sallis R, Young DR, Tartof SY, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. *Br J Sports Med* 2021;55:1099–105.

17 von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLOS Med* 2007;4:e229.

18 National Institutes of Health (NIH). Clinical spectrum of SARS-CoV-2 infection, 2021. Available: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ [Accessed 23 Jul 2021].

19 MacDonald C-J, Madikia A-L, Lajous M, et al. Associations between physical activity and incident hypertension across strata of body mass index: a prospective investigation in a large cohort of French women. *J Am Heart Assoc* 2020;9:e015121.

20 Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: an update of activity codes and met intensities. *Med Sci Sports Exerc* 2000;32:S498–516.

21 Buuren SV, Groothuis-Oudshoorn K. : Multivariate Imputation by Chained Equations in *J Stat Softw* 2011;45:1–67.

22 Rubin DB. Multiple imputation for nonresponse in surveys. *John Wiley & Sons*, 2004.

23 Hamer M, Kivimäki M, Gale CR, et al. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. *Brain Behav Immun* 2020;87:184–7.

24 Yuan Q, Huang H-Y, Chen X-L, et al. Does pre-existing physical inactivity have a role in the severity of COVID-19? *Ther Adv Respir Dis* 2021;15:17534666211025221.

25 de Souza RR, Motta-Santos D, Dos Santos Soares D, et al. Association of physical activity levels and the prevalence of COVID-19-associated hospitalization. *J Med Sport Med* 2021;24:913–8.

26 Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. *JAMA* 2018;320:2020–8.

27 Zheng X, Li X, Sun Z, et al. Physical activity and COVID-19: an observational and Mendelian randomisation study. *J Glob Health* 2020;10:020514.

28 Takavol Z, Ghannadi S, Tabesh MR, et al. Relationship between physical activity, healthy lifestyle and COVID-19 disease severity; a cross-sectional study. *Z Gesundheitswiss* 2021;79:1–9.

29 Laddu DR, Lavie CJ, Phillips SA, et al. Physical activity for immunity protection: inoculating populations with healthy living medicine in preparation for the next pandemic. *Prog Cardiovasc Dis* 2021;64:102–4.

30 Wong C-M, Lai H-K, Ou C-Y, et al. Is exercise protective against influenza-associated mortality? *PLOS One* 2008;3:e2108.

31 Su E, Campbelli MA, Kwong JC. Physical activity and influenza-coded outpatient visits, a population-based cohort study. *PLOS One* 2012;7:e39518.

32 Freeman DC. Coronavirus disease-2019: a tocsin to our aging, unfit, corpulent, and immunodeficient Society. *J Sport Health Sci* 2020;9:293–301.
Brawner CA, Ehrman JK, Bole S, et al, eds. Inverse relationship of maximal exercise capacity to hospitalization secondary to coronavirus disease 2019. Mayo Clinic Proceedings. Elsevier, 2021.

34 Simpson RJ, Kunz H, Agha N, et al. Exercise and the regulation of immune functions. Prog Mol Biol Transl Sci 2015;135:355–80.

35 Nieman DC, Wentz LM. The compelling link between physical activity and the body's defense system. J Sport Health Sci 2019;8:201–17.

36 Hamer M, Sobia S, Batty GD, et al. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation 2012;126:928–33.

37 Monteiro RC. Immunoglobulin A as an anti-inflammatory agent. Clin Exp Immunol 2014;178 Suppl 1:108–10.

38 Pascoe AR, Fiatarone Singh MA, Edwards KM. The effects of exercise on vaccination responses: a review of chronic and acute exercise interventions in humans. Brain Behav Immun 2014;39:33–41.

39 Gualano B, Lemos IR, Silva RP, et al. Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Brain Behav Immun 2022;101:49–56.

40 Zhang H, Chen T, Ren J, et al. Pre-Operative exercise therapy triggers anti-inflammatory trained immunity of Kupffer cells through metabolic reprogramming. Nat Metab 2021;3:843–58.

41 Netea MG, Giamarellos-Bourboulis EJ, Dominguez-Andrés J, et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell 2020;181:969–77.

42 Schwellnus M, Soligard T, Alonso J-M, et al. How much is too much? (Part 2) International Olympic Committee consensus statement on load in sport and risk of illness. Br J Sports Med 2016;50:1043–52.

43 Fournier A, Dos Santos G, Guillas G, et al. Recent recreational physical activity and breast cancer risk in postmenopausal women in the E3N cohort. Cancer Epidemiol Biomarkers Prev 2014;23:1893–902.

44 Stamatakis E, Lee I-M, Bennie J, et al. Does strength-promoting exercise confer unique health benefits? A pooled analysis of data on 11 population cohorts with all-cause, cancer, and cardiovascular mortality endpoints. Am J Epidemiol 2018;187:1102–12.